Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.
Identifieur interne : 001260 ( PubMed/Corpus ); précédent : 001259; suivant : 001261Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.
Auteurs : O. Rascol ; J G Nutt ; O. Blin ; C G Goetz ; J M Trugman ; C. Soubrouillard ; J H Carter ; L J Currie ; N. Fabre ; C. Thalamas ; W W Giardina ; S. WrightSource :
- Archives of neurology [ 0003-9942 ] ; 2001.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Dopamine Agonists (administration & dosage), Dose-Response Relationship, Drug, Double-Blind Method, Dyskinesia, Drug-Induced, Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Prodrugs (administration & dosage), Prodrugs (adverse effects), Pyridines (administration & dosage), Pyridines (adverse effects), Receptors, Dopamine D1 (drug effects), Tetrahydronaphthalenes (administration & dosage), Tetrahydronaphthalenes (adverse effects).
- MESH :
- chemical , administration & dosage : Dopamine Agonists, Prodrugs, Pyridines, Tetrahydronaphthalenes.
- chemical , adverse effects : Prodrugs, Pyridines, Tetrahydronaphthalenes.
- chemical , drug effects : Receptors, Dopamine D1.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Dyskinesia, Drug-Induced, Female, Humans, Male, Middle Aged.
Abstract
Dyskinesias are a frequent adverse effect of long-term levodopa therapy. The relative contribution of dopamine D(1) and D(2) receptor function to the pathophysiology of levodopa-induced dyskinesias remains a matter of controversy.
PubMed: 11176963
Links to Exploration step
pubmed:11176963Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name>
<affiliation><nlm:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allées Jules Guesde, 31073 Toulouse Cedex, France. rascol@cict.fr</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nutt, J G" sort="Nutt, J G" uniqKey="Nutt J" first="J G" last="Nutt">J G Nutt</name>
</author>
<author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O" last="Blin">O. Blin</name>
</author>
<author><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C G" last="Goetz">C G Goetz</name>
</author>
<author><name sortKey="Trugman, J M" sort="Trugman, J M" uniqKey="Trugman J" first="J M" last="Trugman">J M Trugman</name>
</author>
<author><name sortKey="Soubrouillard, C" sort="Soubrouillard, C" uniqKey="Soubrouillard C" first="C" last="Soubrouillard">C. Soubrouillard</name>
</author>
<author><name sortKey="Carter, J H" sort="Carter, J H" uniqKey="Carter J" first="J H" last="Carter">J H Carter</name>
</author>
<author><name sortKey="Currie, L J" sort="Currie, L J" uniqKey="Currie L" first="L J" last="Currie">L J Currie</name>
</author>
<author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N" last="Fabre">N. Fabre</name>
</author>
<author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C" last="Thalamas">C. Thalamas</name>
</author>
<author><name sortKey="Giardina, W W" sort="Giardina, W W" uniqKey="Giardina W" first="W W" last="Giardina">W W Giardina</name>
</author>
<author><name sortKey="Wright, S" sort="Wright, S" uniqKey="Wright S" first="S" last="Wright">S. Wright</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2001">2001</date>
<idno type="RBID">pubmed:11176963</idno>
<idno type="pmid">11176963</idno>
<idno type="wicri:Area/PubMed/Corpus">001260</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001260</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name>
<affiliation><nlm:affiliation>Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allées Jules Guesde, 31073 Toulouse Cedex, France. rascol@cict.fr</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nutt, J G" sort="Nutt, J G" uniqKey="Nutt J" first="J G" last="Nutt">J G Nutt</name>
</author>
<author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O" last="Blin">O. Blin</name>
</author>
<author><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C G" last="Goetz">C G Goetz</name>
</author>
<author><name sortKey="Trugman, J M" sort="Trugman, J M" uniqKey="Trugman J" first="J M" last="Trugman">J M Trugman</name>
</author>
<author><name sortKey="Soubrouillard, C" sort="Soubrouillard, C" uniqKey="Soubrouillard C" first="C" last="Soubrouillard">C. Soubrouillard</name>
</author>
<author><name sortKey="Carter, J H" sort="Carter, J H" uniqKey="Carter J" first="J H" last="Carter">J H Carter</name>
</author>
<author><name sortKey="Currie, L J" sort="Currie, L J" uniqKey="Currie L" first="L J" last="Currie">L J Currie</name>
</author>
<author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N" last="Fabre">N. Fabre</name>
</author>
<author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C" last="Thalamas">C. Thalamas</name>
</author>
<author><name sortKey="Giardina, W W" sort="Giardina, W W" uniqKey="Giardina W" first="W W" last="Giardina">W W Giardina</name>
</author>
<author><name sortKey="Wright, S" sort="Wright, S" uniqKey="Wright S" first="S" last="Wright">S. Wright</name>
</author>
</analytic>
<series><title level="j">Archives of neurology</title>
<idno type="ISSN">0003-9942</idno>
<imprint><date when="2001" type="published">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Dopamine Agonists (administration & dosage)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Prodrugs (administration & dosage)</term>
<term>Prodrugs (adverse effects)</term>
<term>Pyridines (administration & dosage)</term>
<term>Pyridines (adverse effects)</term>
<term>Receptors, Dopamine D1 (drug effects)</term>
<term>Tetrahydronaphthalenes (administration & dosage)</term>
<term>Tetrahydronaphthalenes (adverse effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agonists</term>
<term>Prodrugs</term>
<term>Pyridines</term>
<term>Tetrahydronaphthalenes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Prodrugs</term>
<term>Pyridines</term>
<term>Tetrahydronaphthalenes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine D1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dyskinesias are a frequent adverse effect of long-term levodopa therapy. The relative contribution of dopamine D(1) and D(2) receptor function to the pathophysiology of levodopa-induced dyskinesias remains a matter of controversy.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11176963</PMID>
<DateCreated><Year>2001</Year>
<Month>02</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted><Year>2001</Year>
<Month>03</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-9942</ISSN>
<JournalIssue CitedMedium="Print"><Volume>58</Volume>
<Issue>2</Issue>
<PubDate><Year>2001</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Archives of neurology</Title>
<ISOAbbreviation>Arch. Neurol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.</ArticleTitle>
<Pagination><MedlinePgn>249-54</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dyskinesias are a frequent adverse effect of long-term levodopa therapy. The relative contribution of dopamine D(1) and D(2) receptor function to the pathophysiology of levodopa-induced dyskinesias remains a matter of controversy.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To establish whether a selective D(1) dopamine agonist induces more or less dyskinesia than levodopa in primed dyskinetic patients with Parkinson disease.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We studied ABT-431, the prodrug of a fully selective D(1) agonist, in 20 subjects with advanced Parkinson disease and a fluctuating response to levodopa complicated by dyskinesias. Eight patients were studied in a double-blind, randomized design (French centers); 12, in an open, randomized design (US centers). We assessed and compared the antiparkinsonian (Unified Parkinson's Disease Rating Scale) and dyskinetic (response induced by an acute challenge of a suprathreshold dose of levodopa and by 4 different ascending doses (5, 10, 20, and 40 mg) of ABT-431 during the 6 hours after the challenge.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The separate analysis of the double-blind and open data led to the same findings, ie, the antiparkinsonian and dyskinetic responses induced by ABT-431 were dose related. At the most effective doses (20 and 40 mg), ABT-431 exhibited similar antiparkinsonian benefit and produced similar dyskinesias as levodopa.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Dopamine D(1) agonists can induce a full antiparkinsonian response but do not support previous hypotheses suggesting that D(1) agonists are more or less likely to produce dyskinesias than levodopa.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rascol</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allées Jules Guesde, 31073 Toulouse Cedex, France. rascol@cict.fr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nutt</LastName>
<ForeName>J G</ForeName>
<Initials>JG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Blin</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Goetz</LastName>
<ForeName>C G</ForeName>
<Initials>CG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Trugman</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Soubrouillard</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Carter</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Currie</LastName>
<ForeName>L J</ForeName>
<Initials>LJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fabre</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Thalamas</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Giardina</LastName>
<ForeName>W W</ForeName>
<Initials>WW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wright</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Arch Neurol</MedlineTA>
<NlmUniqueID>0372436</NlmUniqueID>
<ISSNLinking>0003-9942</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011355">Prodrugs</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>69MG3OZA0H</RegistryNumber>
<NameOfSubstance UI="C095428">adrogolide hydrochloride</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004409" MajorTopicYN="Y">Dyskinesia, Drug-Induced</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011355" MajorTopicYN="N">Prodrugs</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013764" MajorTopicYN="N">Tetrahydronaphthalenes</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year>
<Month>2</Month>
<Day>15</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2001</Year>
<Month>4</Month>
<Day>3</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2001</Year>
<Month>2</Month>
<Day>15</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">11176963</ArticleId>
<ArticleId IdType="pii">noc00056</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001260 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001260 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:11176963 |texte= Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:11176963" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |